2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma.

abstract：:The prognostic significance of O6-methylguanine DNA methyltransferase (MGMT) inactivation was evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in addition to rituximab. In this retrospective study, we used the methylation-sp...

journal_title：Leukemia & lymphoma

authors： Lee GW,Kang JH,Kim IS,Kim HG,Ko GH,Lee JH,Kim DC,Song DH,Yang JW,Lee JS

更新日期：2009-12-01 00:00:00

abstract：:To evaluate the prognostic impact of melphalan dose and total body irradiation (TBI) use in acute myeloid leukemia patients undergoing reduced-intensity allogeneic transplantation, we retrospectively compared outcomes of patients receiving a higher-dose (120-140 mg/m2, n = 379) or lower-dose melphalan (80-110 mg/m2, n...

journal_title：Leukemia & lymphoma

authors： Harada K,Yanada M,Machida S,Kanamori H,Onizuka M,Ozawa Y,Kobayashi H,Sawa M,Katayama Y,Ohashi K,Kanda J,Ichinohe T,Atsuta Y,Yano S

更新日期：2019-06-01 00:00:00

abstract：:Impressive gains have been made in the therapy of childhood acute lymphoblastic leukemia (ALL) in recent years such that remissions today are commonly achieved in up to 95% of patients and long term disease-free survival rates approach 70%. Methotrexate is a key component in ALL consolidation and maintenance therapies...

journal_title：Leukemia & lymphoma

authors： Matherly LH,Taub JW

更新日期：1996-05-01 00:00:00

abstract：:Plasmablastic lymphoma (PBL) is a distinct variant of diffuse large B-cell lymphoma initially described in HIV-positive patients. Several studies have reported the occurrence of PBL in HIV-negative patients, but comparative data are lacking. The goal of this study was to compare the characteristics of HIV-positive and...

journal_title：Leukemia & lymphoma

authors： Castillo JJ,Winer ES,Stachurski D,Perez K,Jabbour M,Milani C,Colvin G,Butera JN

更新日期：2010-11-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph) translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the standard therapy for Ph-positive CML. Achievement of deep molecular responses (typically defined as ≥4-log reduction in BCR-AB...

journal_title：Leukemia & lymphoma

authors： Arora R,Press RD

更新日期：2017-01-01 00:00:00

abstract：:An unusual case of aplastic anemia presenting in association with lymphoplasmacytic lymphoma and paroxysmal nocturnal hemoglobinuria is discussed. An insult to the hematological stem cell compartment may result in multiple pathological entities, potentially influencing our approach to the treatment of hematological cl...

journal_title：Leukemia & lymphoma

authors： Veidt RG,Ansari-Lari A,Brodsky RA

更新日期：2005-08-01 00:00:00

abstract：:Data from 29,845 patients with lymphomas, 981 of whom had lymphoma as a second primary tumor, registered in the Surveillance Epidemiology and End Results (SEER) program in the U.S.A. between 1973 and 1986 were analyzed. The characteristics of the 274 patients with lymphoma as a second tumor who had received chemothera...

journal_title：Leukemia & lymphoma

authors： Robinson E,Bar-Deroma R,Epelbaum R,Rennert G,Neugut AI

更新日期：1996-01-01 00:00:00

abstract：:The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

journal_title：Leukemia & lymphoma

authors： Horowitz HW,Holmgren D,Seiter K

更新日期：1996-09-01 00:00:00

abstract：:Recombinant interleukin-21 (IL-21) has potential utility in cancer therapy. Stimulation with IL-21 can induce apoptosis in follicular lymphoma (FL) cells, and existing studies have suggested that IL-21 signaling may function in tumor suppression. In order to elucidate the relationship between IL-21 receptor (IL-21R) e...

journal_title：Leukemia & lymphoma

authors： Wood B,Sikdar S,Choi SJ,Virk S,Alhejaily A,Baetz T,LeBrun DP

更新日期：2013-06-01 00:00:00

abstract：:Since rising serum lactate dehydrogenase (LDH) heralds progression in patients with lymphoma or myeloma we investigated the significance of its elevations during chemotherapy supported by granulocyte (G-) or Granulocyte-Macrophage (GM-) colony stimulating factors (CSF). To Exclude effects of resistant disease we analy...

journal_title：Leukemia & lymphoma

authors： Sarris AH,Majlis A,Dimopoulos MA,Younes A,Swann F,Rodriguez MA,McLaughlin P,Cabanillas F

更新日期：1995-05-01 00:00:00

abstract：:There is insufficient information on the characteristics of chronic lymphocytic leukemia (CLL) in Latin American patients. Immunoglobulin variable-region heavy-chain (IGVH) gene usage and mutation status and prognostic factors were investigated in patients resident in Venezuela. The most frequently used IGVH family ge...

journal_title：Leukemia & lymphoma

authors： Marquez ME,Deglesne PA,Lopez JL,Da Costa O,Borrego M,Hernández M,Muller A,Ajchenbaum-Cymbalista F,Romano E

更新日期：2012-02-01 00:00:00

abstract：:The HD-9 trial showed that eight cycles of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine)-escalated led to significant improvements in response rate, progression-free survival and overall survival over COPP/ABVD (cyclophosphamide, vincristine, prednisone, procarbaz...

journal_title：Leukemia & lymphoma

authors： Belada D,Štěpánková P,Sýkorová A,Žák P,Smolej L

更新日期：2015-07-01 00:00:00

abstract：:Human mantle cell lymphoma (MCL) cell lines are scarce and have been only sporadically described and validated, and only a few have been thoroughly molecularly or genetically characterized. We describe here the successful establishment of a new MCL line, PF-1, with typical MCL characteristics. Culturing primary MCL ce...

journal_title：Leukemia & lymphoma

authors： Pham LV,Vang MT,Tamayo AT,Lu G,Challagundla P,Jorgensen JL,Rollo AA,Ou Z,Zhang L,Wang M,Ford RJ

更新日期：2015-01-01 00:00:00

abstract：:Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

journal_title：Leukemia & lymphoma

authors： Cummins KD,Gill S

更新日期：2018-07-01 00:00:00

abstract：:The mammalian target of rapamycin (mTOR) is an important protein kinase regulating cell survival and apoptosis. To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 ...

journal_title：Leukemia & lymphoma

authors： Huang L,Huang J,Wu P,Li Q,Rong L,Xue Y,Lu Q,Li J,Tong N,Wang M,Zhang Z,Fang Y

更新日期：2012-05-01 00:00:00

abstract：:The classification of germinal centre (GC) and non-GC is an important prognostic immunophenotype for patients with diffuse large B cell lymphoma (DLBCL) following anthracycline-based chemotherapy. The expression of the anti-apoptotic protein, Bcl-2, has been associated with an unfavourable prognosis in patients with D...

journal_title：Leukemia & lymphoma

authors： Song MK,Chung JS,Shin DH,Seol YM,Shin HJ,Choi YJ,Cho GJ

更新日期：2009-01-01 00:00:00

abstract：:Safety testing for replication-competent retrovirus (RCR) is an important requirement in gene transfer clinical trials using retroviral vectors. A sensitive polymerase chain reaction (PCR) method is one approach to RCR detection. Only in the presence of RCR will the pol-env encoding sequences, necessary for viral repl...

journal_title：Leukemia & lymphoma

authors： Allan DS,De Koven A,Wild A,Kamel-Reid S,Dubé ID

更新日期：1996-10-01 00:00:00

abstract：:Beclin-1 is a key regulator of autophagy and has been suggested to be involved in the development of drug resistance in multiple myeloma (MM). We analyzed the expression of Beclin-1 in a retrospective cohort of 70 MMs. Beclin-1 expression did not influence overall survival (OS) and progression-free survival (PFS) in p...

journal_title：Leukemia & lymphoma

authors： Willenbacher W,Thangavadivel S,Greil R,Willenbacher E,Weger R,Manzl C,Jöhrer K,Brunner A

更新日期：2016-10-01 00:00:00

abstract：:Bone marrow toxicity is a great challenge for physicians treating patients with non-Hodgkin's lymphoma (NHL) and prescribed chemotherapy. Granulocyte colony-stimulating factor (G-CSF) prevents myelotoxicity, but the optimal timing and scheduling of G-CSF administration has not been ascertained. We investigated leukocy...

journal_title：Leukemia & lymphoma

authors： Sawada KI,Sato N,Kohno M,Hannda H,Yasukouchi T,Tanngo M,Hirayama A,Koike T

更新日期：1995-12-01 00:00:00

abstract：:There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients ...

journal_title：Leukemia & lymphoma

authors： Lee HK,Wilder RB,Jones D,Ha CS,Pro B,Rodriguez MA,Romaguera JE,Cabanillas F,Rodriguez J,Cox JD

更新日期：2002-09-01 00:00:00

abstract：:This study describes our institution's experience using whole brain radiation therapy (WBRT) to treat patients with acute myelogenous leukemia (AML) presenting with hyperleukocytosis. After approval by the institutional review board, we identified patients with AML and hyperleukocytosis using hospital records. The pri...

journal_title：Leukemia & lymphoma

authors： Ferro A,Jabbour SK,Taunk NK,Aisner J,Cohler A,Somalya S,Goyal S

更新日期：2014-01-01 00:00:00

abstract：:Chemotherapy has long been integral to the treatment of chronic lymphocytic leukemia (CLL). Fludarabine/cyclophosphamide, chlorambucil and bendamustine are commonly used as a backbone, depending on the patient's age and general health. The advent of the anti-CD20 monoclonal antibodies, such as rituximab and obinutuzum...

journal_title：Leukemia & lymphoma

authors： Wendtner CM,Gregor M

更新日期：2018-02-01 00:00:00

abstract：:Until recently, combination chemotherapy with melphalan and prednisone (MP) has remained the most widely accepted treatment option for elderly patients with multiple myeloma (MM). However, since the availability of new and more active drugs, several groups have compared in several phase III trials the efficacy and saf...

journal_title：Leukemia & lymphoma

authors： De La Rubia J,Sanz MA

更新日期：2011-01-01 00:00:00

abstract：:This study evaluated whether measures of psychological well-being, including coping style, are associated with advance care planning (ACP). Data were from the Hematology Communications Study (HEMA-COMM), a prospective observational study of physician-patient communication in patients with hematologic malignancies. ACP...

journal_title：Leukemia & lymphoma

authors： Loberiza FR Jr,Swore-Fletcher BA,Block SD,Back AL,Goldman RE,Tulsky JA,Lee SJ

更新日期：2011-12-01 00:00:00

abstract：:Rituximab maintenance (RM) improves time to progression (PFS) in advanced follicular lymphoma (FL), but the impact of various RM schedules remains unknown. This study performed a retrospective evaluation of RM given for up to 2 years vs observation in 319 untreated FL patients (stage II-IV; grade 1-3A) responding to R...

journal_title：Leukemia & lymphoma

authors： Janikova A,Bortlicek Z,Campr V,Kopalova N,Benesova K,Hamouzova J,Belada D,Prochazka V,Pytlik R,Vokurka S,Pirnos J,Duras J,Mocikova H,Mayer J,Trneny M

更新日期：2016-05-01 00:00:00

abstract：:High dose chemotherapy with autologous stem cell transplantation (ASCT) improves outcomes in patients 65 years of age or less with multiple myeloma. Survival and costs in a cohort of 16 patients who received melphalan and prednisone as part of a clinical trial were compared with those of 36 patients referred to our ce...

journal_title：Leukemia & lymphoma

authors： Kouroukis CT,O'Brien BJ,Benger A,Marcellus D,Foley R,Garner J,Ingram C,Haines P,Henderson-O'Connor N,Meyer R

更新日期：2003-01-01 00:00:00

abstract：:High-dose melphalan therapy with peripheral blood stem cell (PBSC) transplantation is a standard treatment for younger patients with untreated multiple myeloma that results in high overall and complete response (CR) rates, and improved event-free and overall survival compared with standard chemotherapy alone. Inductio...

journal_title：Leukemia & lymphoma

authors： Oakervee H,Popat R,Cavenagh JD

更新日期：2007-10-01 00:00:00

abstract：:We have recently shown that antibodies to transcobalamin II (TCII) inhibit the in vitro growth of human and murine leukemic cells. This antiproliferative strategy targets the uptake of cobalamin (Cbl), an essential cofactor for two biochemical reactions in humans. To date there has been no appropriate cell culture mod...

journal_title：Leukemia & lymphoma

authors： McLean GR,Williams MJ,Woodhouse CS,Ziltener HJ

更新日期：1998-06-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with an association with inflammation and viral infections. We hypothesize that environmental factors may be involved in the pathogenesis of DLBCL. In this study, we compared gene expression profiles of lymph node tissues from patients with DLBCL from tw...

journal_title：Leukemia & lymphoma

authors： Högfeldt T,Bahnassy AA,Kwiecinska A,Osterborg A,Tamm KP,Porwit A,Zekri AR,Lundahl J,Khaled HM,Mellstedt H,Moshfegh A

更新日期：2013-05-01 00:00:00

abstract：:Despite individual differences between certain leukemias, the overall survival rate in acute leukemia remains low at approximately 40%. Novel therapeutics, including targeted therapies like tyrosine kinase inhibitors, have been incorporated into treatment regimens, but most have failed at eradicating leukemic stem cel...

journal_title：Leukemia & lymphoma

authors： Karantanou C,Godavarthy PS,Krause DS

更新日期：2018-11-01 00:00:00